Table of Contents
This study encompasses insulin drugs and delivery in pharmaceutical and biotechnology markets with its classification and its usage in diabetes types. The study includes market projections through the end of 2013 and for a five-year period until 2018.
- The global market for insulin drug and delivery devices totaled $24 billion in 2012. The overall insulin drug and device market is projected to be worth $25.7 million by 2013 and $40.2 billion by 2018, a five-year compound annual growth rate (CAGR) for of 9.3% from 2013 to 2018.
- The insulin vial and syringe segment had a market value of $13.7 billion in 2012. It is expected to reach $14.7 billion by 2013 and $23.3 billion by 2018 with a CAGR of 9.6%. - The insulin pens market totaled nearly $9.4 billion in 2012. This market is expected to reach $10 billion in 2013 and $15.4 billion by 2018, a CAGR of 8.9%.
BCC Research’s objective in carrying out this study is to provide an overview of the current and future characteristics of the global market for emerging insulin drugs and delivery technologies. The fundamental objective is to present a comprehensive analysis and identify the future direction of insulin drugs and delivery devices as important tools in treating diabetes with well-tolerated delivery devices. This report explores present and future strategies within the insulin drug and delivery market, which includes syringes, pumps, pens and many newer methods. The market’s improvisation, setbacks and needs are also discussed. The classifications, comparisons and usage of different insulin types and devices are presented as well.
A detailed analysis of insulin drugs and delivery industry structure has been conducted. Revenues are broken down by type, as well as by region. Sales figures are estimated for the five-year period from 2013 through 2018. Applications for insulin drugs and delivery are also discussed in a separate section, with emphasis on their usage in treating different types of diabetes. The report also covers significant patents and their allotments in each category.
REASONS FOR DOING THIS STUDY
The emerging technologies in the insulin drug and delivery field have potential in the diabetes market, with improved glucose control, along with improved and well-accepted newer delivery methods. Modern industries and research institutes have begun to explore newer method for diabetes control in adults and juveniles. , leading to a steady market for these technologies.
Research and development (R&D) spending, increasing competition, patent expiries and emerging technologies are guiding this to a new direction. The new advancements, new product launches, and increased awareness and early detection of the disease have influenced the market to grow in the foreseeable future. This study looks at many of the systems affected by these factors. Companies’ acquisition strategies and collaborations are covered in this report. This study also discusses the strength and weaknesses of each technology type in light of the new technologies, growing competition and changing customer needs.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This study contributes to the areas of market growth for insulin drug and delivery manufacturers and users. It will be of interest to pharmaceutical biotechnical companies, research institutes, hospitals and physicians.
SCOPE OF THE STUDY
The scope of this study encompasses insulin drugs and delivery in pharmaceutical and biotechnology markets with its classification and its usage in diabetes types. BCC analyzes each market and its applications, as well as its regulatory environment, technology and market share. The markets, such as type 1 diabetes, type 2 diabetes and gestational diabetes, are analyzed for the years 2011 and 2012. The markets are projected through the end of 2013 and for a five-year period until 2018. The market is also segmented by insulin syringes and vials, insulin pens and insulin pumps. Technological issues include the latest trends and developments. The study also includes the patent identifications for insulin as a drug, along with its deliveries.
The emerging markets for insulin drug and delivery include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.
Both primary and secondary research methodologies were used in the preparation of this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, as well as many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Spain Diabetes Care Devices Market Outlook to 2022 - Glucose Monitoring and Insulin Delivery Summary GlobalData’s new report, "Spain Diabetes Care Devices Market Outlook to 2022", provides key market ...
China Diabetes Care Devices Market Outlook to 2022 - Glucose Monitoring and Insulin Delivery Summary GlobalData’s new report, "China Diabetes Care Devices Market Outlook to 2022", provides key market ...
South Korea Diabetes Care Devices Market Outlook to 2022 - Glucose Monitoring and Insulin Delivery Summary GlobalData’s new report, "South Korea Diabetes Care Devices Market Outlook to 2022", provides ...